The EPA
Drug Initiative

Make your voice heard, urge the FDA to approve Vascepa for mixed dyslipidemia

"I strongly support the use of EPA-only Vascepa as a tool for the reduction of residual lipoprotein risk in my patients on statin therapy with triglycerides above 250 mg/dl. This treatment is safe, improves biomarkers of disease , and is being currently being evaluated by a landmark Clinical outcomes trial, REDUCE-IT."

Gregory S Pokrywka
MD FACP FNLA NCMP
Prevention of Cardiovascular Disease and Women’s Menopausal Health • Assistant Professor of General Internal Medicine • Johns Hopkins University School of Medicine • Diplomate American Board Clinical Lipidology and Fellow, National Lipid Assn. • Certified Menopause Practitioner: North American Menopause Society • Director: Baltimore Lipid Center. Board Member, South East Lipid Assn.

The Editor’s Roundtable: Hypertriglyceridemia
Vincent E. Friedewald, MDa, Christie M. Ballantyne, MDb and Peter H. Jones, MDd

Hypertriglyceridemia is defined as a fasting serum triglyceride (TG) level of ≥150 mg/dl. Serum TG elevations are designated as:

Currently, 31% of the population in the United States have TGs >150 mg/dl, unchanged for the past 2 decades. Mexican Americans have the highest rates of hypertriglyceridemia, with 9% of Mexican American men aged 50 to 59 years having very high TGs compared with 1% to 2% of the overall population with very high TGs. African-Americans have the lowest prevalence (15.6%) of hypertriglyceridemia.

Although hypertriglyceridemia affects so many persons, its clinical significance is unclear—except for the long-established relation between very high TGs and pancreatitis. Whether elevated TGs are a direct cause or only a marker for atherosclerosis has been a topic of debate for many years. This question and other issues, including evaluation and best treatment of patients with elevated TGs, are addressed in this Editor’s Roundtable.

Read More

I've been taking Vascepa for 5 months and I can report the results have been excellent. My triglycerides went from 440 mg/dL to under 190 mg/dL. I've also noticed another benefit besides lower Triglycerides which is less eye inflammation. I've suffered from Dry Eye Syndrome for over 30 year and since taking Vascepa my eyes are much improved and I haven't had the need for eye drops.

John Cappello
Middlebury, CT
Back To Top